Manager TitleAgeSince
Chief Executive Officer 53 29/08/2022
Director of Finance/CFO 55 01/05/2023
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 31/08/2015
Chairman 71 14/04/2021
Director/Board Member 59 14/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
-0.11%-2.38%+2.06%+19.57% 48.84B
+1.89%+4.36%+494.71%+637.45% 45.44B
+1.83%+2.83%+14.87%+91.99% 41.22B
-0.50%-0.81%+25.61%+12.05% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+0.59%-2.65% - - 16.25B
-1.14%-2.01%+28.93%+132.78% 16.67B
-0.49%-0.54%+2.96%+27.12% 14.08B
-2.60%+0.79%+78.19%+39.69% 13.68B
Average +0.26%-0.78%+83.08%+127.09% 29.83B
Weighted average by Cap. -0.02%-0.84%+104.53%+155.24%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock